GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE25nnn/GSE25766/primaryOK2000000GenomicsMus musculusExpression profiling by arrayhttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE25766GEOGSE0falseCardiac gene expression profiling of heart failure treatment with the anti-ischemic drug ranolazineHeart failure is a leading cause of cardiovascular mortality with limited options for treatment. We analyzed whether the anti-ischemic drug ranolazine could retard the progression of heart failure in an experimental model of heart failure induced by 6 months of chronic pressure overload. The study showed that 2 months of ranolazine treatment improved cardiac function of aortic constricted C57BL/6J (B6) mice with symptoms of heart failure as assessed by echocardiography. The microarray gene expression study of heart tissue from failing hearts relative to ranolazine-treated and healthy control hearts identified heart failure-specific genes that were normalized during treatment with the anti-ischemic drug ranolazine.2010/12/03GSE25766GSM632870GSM632871GSM632872GSM632877GSM632878GSM632869126125766Mus musculus[21711241][34576047]